BTAI — BioXcel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1720893 ·
Last close
$0.81
Market Cap
$24.95M
52W High
$1.46
52W Low
$0.74
ADV30
1,156,747
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 206,000 | -77,000 | -10,223,000 | -12,691,000 | 34,025,000 | 17,180,000 | 139,568,000 |
| Dec 2025 | 256,000 | 224,000 | -10,282,000 | -12,545,000 | 44,916,000 | 28,415,000 | 140,379,000 |
| Sep 2025 | 98,000 | 87,000 | -14,034,000 | -30,911,000 | 44,792,000 | 36,176,000 | 133,711,000 |
| Jun 2025 | 120,000 | 13,000 | -15,852,000 | -19,187,000 | 25,789,000 | 17,435,000 | 133,456,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-57,381,000
Investing CF
$0
Financing CF
$43,548,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.67
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-732,785,000
Inventory
$500,000
Receivables
$216,000
ST Investments
—
EBIT TTM
$-58,145,000
Pretax Income TTM
$-75,334,000
Interest Exp TTM
$17,189,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$680,000
EBITDA
$-50,109,000
Free Cash Flow
$-34,118,500
Enterprise Value
$108,058,104
Total Cash
$17,180,000
Total Debt
$100,289,000
Shares Out
30,877,605
Trailing EPS
$-4.77
Book Value
$-3.90
ROE
—
ROA
-86.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,000 | -50,267,000 | -69,897,000 | 44,916,000 | 140,379,000 | — | -57,615,000 |
| Dec 2024 | 2,266,000 | -64,804,000 | -59,599,000 | 38,338,000 | 131,439,000 | — | -72,027,000 |
| Dec 2023 | 1,380,000 | -167,619,000 | -179,053,000 | 73,702,000 | 130,210,000 | — | -155,006,000 |
| Dec 2022 | 375,000 | -159,645,000 | -165,757,000 | 205,853,000 | 129,078,000 | — | -135,341,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RADX | Radiopharm Theranostics Ltd | $24.83M | $3.15 | — |
| QUCY | Quantum Cyber N.V. | $25.95M | $1.14 | — |
| AYTU | AYTU BIOPHARMA, INC | $23.94M | $2.23 | — |
| CRVO | CervoMed Inc. | $23.89M | $2.58 | — |
| IGC | IGC Pharma, Inc. | $26.09M | $0.25 | — |
News headlines (Yahoo Finance, 1h cache)
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
2026-06-02 16:00 · Yahoo
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
2026-05-28 11:00 · Yahoo
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
2026-05-15 12:15 · Yahoo
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 11:00 · Yahoo
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
2026-05-14 12:45 · Yahoo
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 23:05 · Yahoo
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
2026-05-04 14:00 · Yahoo
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns
2026-04-17 13:36 · Yahoo
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
2026-04-17 11:00 · Yahoo
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks
2026-04-13 16:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.